| Old-school chemotherapy in immunotherapeutic combination in cancer, a low-cost drug repurposed R Abu Eid, GSE Razavi, M Mkrtichyan, J Janik, SN Khleif Cancer immunology research 4 (5), 377-382, 2016 | 50 | 2016 |
| An investigation of the spectrum of common and rare inherited coagulation disorders in north-eastern Iran H Mansouritorghabeh, L Manavifar, A Banihashem, A Modaresi, A Shirdel, ... Blood Transfusion 11 (2), 233, 2013 | 46 | 2013 |
| Can malignant bowel obstruction in advanced cancer patients be treated at home? G Porzio, F Aielli, L Verna, B Galletti, G Shoja e Razavi, C Ficorella Supportive Care in Cancer 19, 431-433, 2011 | 34 | 2011 |
| Comparison of HTLV-I proviral load in adult T cell leukemia/lymphoma (ATL), HTLV-I-associated myelopathy (HAM-TSP) and healthy carriers MM Akbarin, H Rahimi, T HassanNia, GS Razavi, F Sabet, A Shirdel Iranian Journal of Basic Medical Sciences 16 (3), 208, 2013 | 33 | 2013 |
| Emerging role of interleukins in cancer treatment GSE Razavi, T Allen Immunome Research 11 (S2), 1, 2015 | 20 | 2015 |
| Agonist anti-GITR antibody significantly enhances the therapeutic efficacy of Listeria monocytogenes-based immunotherapy R Shrimali, S Ahmad, Z Berrong, G Okoev, A Matevosyan, GSE Razavi, ... Journal for ImmunoTherapy of Cancer 5, 1-9, 2017 | 19 | 2017 |
| Early 3+ 3 trial dose-escalation phase I clinical trial design and suitability for immune checkpoint inhibitors OE Rahma, JE Reuss, A Giobbie-Hurder, G Shoja E Razavi, ... Clinical Cancer Research 27 (2), 485-491, 2021 | 4 | 2021 |
| Targeted Therapy in Myelodysplastic Syndrome T Allen, GSE Razavi EC Cancer 2, 34-44, 2016 | 4 | 2016 |
| Immunotherapy in Hodgkin Lymphoma T Allen, GSE Razavi EC Cancer 2, 93-99, 2016 | 4 | 2016 |
| A review article on emerging role of hybrid molecules in treatment of breast cancer T Allen, GSE Razavi, G Mnv Austin J. Clin. Immunol 1, 1022, 2020 | 3 | 2020 |
| Cancer treatment in the checkpoint inhibitor era GSE Razavi Immunome Research 12 (1), E105, 2016 | 3 | 2016 |
| Immunotherapeutic approach to squamous cell carcinoma of the head and neck T Allen, GSE Razavi EC Cancer 2 (1), 28-33, 2016 | 2 | 2016 |
| A Review Article on Clinical Trials on Hybrid Drugs and Nanohybrid Technologies in Drug Development that Combat Cancer T Allen, MNV Giridhar, GS Razavi JJ Cancer Sci. Res 1 (3), 1-8, 2015 | 2 | 2015 |
| A review on role of peptide vaccines in cancer therapy treatment of cancer disease by peptide vaccine T Allen, MN Giridhar Adv Pharmacol Pharm 2, 96-100, 2014 | 2 | 2014 |
| Panel Discussion: Treatment options for relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL) patients R Foley, C Owen, S Tabchi, G Razavi Canadian Hematology Today, 2022 | | 2022 |
| Immune checkpoint inhibitors induce response in a dose-dependent manner while their immune related adverse events are dose-independent, a meta-analysis O Rahma, J Reuss, A Giobbie-Hurder, G Razavi, P Mehra, S Gupta, ... JOURNAL FOR IMMUNOTHERAPY OF CANCER 7, 2019 | | 2019 |
| Immunotherapy and malignant pleural mesothelioma T Allen, N Sheikh-Khoni, SE Razavi Clin Med 2, 1-6, 2019 | | 2019 |
| Immunotherapy and hepatocellular carcinoma T Allen, N Sheikh, ER Shoja, N Basha Gen 3, 1-7, 2019 | | 2019 |
| Court NB. Immunotherapy and penis cancer T Allen, SE Razavi Pharm Pharmacol Int J 7 (1), 1-3, 2019 | | 2019 |
| Immunotherapy and gastroenteropancreatic neuroendocrine tumor T Allen, N Sheikh, ER Shoja, N Basha Gen 3, 1-7, 2019 | | 2019 |
